The SUMMIT trial (NCT04847557) is currently investigating the effect of tirzepatide, a combined glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, on HF symptoms, cardiovascular death and HF events. Here, GLP1R is linked to hydrops fetalis.